Mushtaq Talib Sahwi AL-Rubaye

Avhandlingen er tilgjengelig her! / The doctoral thesis is available here!

Auditoriet er åpent for publikum, men vil også bli strømmet / The auditorium is open to the public. The defense will still be streamed.
Opptak av disputasen vil være tilgjengelig i et døgn. / A recording of the disputation will be available for 24 hours.        

NB! Prøveforelesning over oppgitt emne starter 23.03.23 kl. 08.00 i Aud Tabletten, Farmasibygget / Note: The trial lecture starts March 23rd at 08.00 in Auditorium Tabletten, Pharmacy building
Tittel/Title:  “Vancomycin resistance in S. aureus - where did it go?”
Prøveforelesningen strømmes her / The trial lecture will be streamed here

Disputasen starter kl. 13.30 / The defense starts at 13.30
Disputasen strømmes her / The defense will be streamed here

Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis

Enterococci are a group of bacteria that naturally live in our gut and acquire genetic material (DNA) that help them become resistant to antibiotics. Vancomycin is an important antibiotic against enterococci that have acquired resistance to commonly used antibiotics. The vancomycin resistant form of enterococci (VRE) is thus an important challenge in healthcare settings globally. VRE can cause serious infections, especially in hospitalized patients with reduced immune system. The incidence of VRE in Norway has been low but increased significantly since 2010.

We collected individual VRE from 2010-15 and compared their DNA to vancomycin susceptible enterococci (VSE) and detected new variants of VRE. The main results showed that the overall situation in Norway is like other European countries with circulation of easily transmissible VSE that later acquire new DNA creating VRE. This is important knowledge to be able to implement targeted measures to prevent the occurrence and spread of VRE.

Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Professor II Kristin Hegstad, Institutt for medisinsk biologi,  Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Biveiledere/supervisors:
Professor Arnfinn Sundsfjord, Institutt for medisinsk biologi,  Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Forsker Jessin Janice James Peter, Institutt for medisinsk biologi, UiT Norges arktiske universitet
Associate professor II Jørgen Vildershøj Bjørnholt, Universitetet i Oslo 

Bedømmelseskomité/Defensecomitee:

Assistant professor Ana Raquel Pinho Freitas, Instittuo Universitario de Ciências da Saude, Gandra, Porto Portugal – 1. opponent.
Senior scientist Henrik Hasman, Statens serum institut, København, Danmark– 2. opponent.
Professor Pål Jarle Johnsen, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité.

Disputasleder/ Leader of defense:
Professor emeritus Tore Jarl Gutteberg, UiT Norges arktiske universitet